Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 10

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  therapeutic target
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Interleukin 7 receptor alpha as a potential therapeutic target in transplantation

100%
Racape M., Vanhove B., Soulillou J.-P., Brouard S.
Archivum Immunologiae et Therapiae Experimentalis
|
2009
|
tom 57
|
nr 4
253-261
2

Structure, regulation and function of PKB-Akt - a major therapeutic target

100%
Hemmings B. A.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
3

Endometriosis — insights into a multifaceted entity

84%
Amalinei C., Pavaleanu I., Lozneanu L., Balan R., Giusca S.-E., Caruntu I.-D.
Folia Histochemica et Cytobiologica
|
2018
|
tom 56
|
nr 2
4

Quantitative immunohistochemistry in lung cancer: clinical perspective

84%
Szutowicz E., Dziadziuszko R.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 1
7-11
5

Leukemia inhibitory factor: a potential biomarker and therapeutic target in pancreatic cancer

84%
Wrona E., Potemski P., Sclafani F., Borowiec M.
Archivum Immunologiae et Therapiae Experimentalis
|
2021
|
tom 69
|
nr 1
6

Oligopeptidase B-2 from Leishmania amazonensis with an unusual C-terminal extension

84%
De M. G. H. L., De Carvalho R. S. N., De Oliveira Gomes D. C., Rossi-Bergmann B., De-Simone S. G.
Acta Parasitologica
|
2008
|
tom 53
|
nr 2
The oligopeptidase B serine protease is an important virulence factor and therapeutic target in Trypanosoma infections. Recently, the Leishmania major Genome Project identified a new oligopeptidase B that was denominated oligopeptidase B-like, herein named oligopeptidase B-2. In this study, a complete open reading frame of oligopeptidase B-2 from Leishmania amazonensis (PH8 strain) was amplified by PCR using primers designed for the oligopeptidase B-2 gene of L. major. The 2,715 bp fragment coded for a protein of 905 amino acids with a predicted molecular mass of 103,918.9 Da and theoretical pI of 5.82. The encoded protein displayed ∼96% identity with L. major and ∼75% identity with Trypanosoma cruzi and T. brucei oligopeptidases B-2, and ∼21% identity with Escherichia coli and L. amazonensis classical oligopeptidase B. An unusual C-terminal extension was found in relation to the classical trypanosomatid oligopeptidase B. By sequence alignment, we determined a catalytic triad (Ser 629, Asp 717 and His 758), S1 subsite (Glu 674 and Glu 676) and suggest a difference in the S2 subsite of L. amazonensis oligopeptidase B-2. We also found that the oligopeptidase B-2 gene is expressed in all cycle stages of L. amazonensis. A phylogenetic analysis indicated that oligopeptidase B-2 is a new member of oligopeptidase B.
7
Content available remote

Inhibition of nuclear factor-kappaB attenuates atherosclerosis in apoE-LDLR - double knockout mice

84%
Jawien J., Gajda M., Mateuszuk L., Olszanecki R., Jakubowski A., Szlachcic A., Karabiowska M., Korbut R.
Journal of Physiology and Pharmacology
|
2005
|
tom 56
|
nr 3
Nuclear factor - B (NF-B) is a good therapeutic target for cardiovascular disease and numerous efforts are being made to develop safe NF-B inhibitors. Nowadays many authors address NF-B as a major therapeutic target in atherosclerosis, especially for preventive measures, in the light of two main hypothesis of atherosclerosis: oxidation and inflammation. We hypothesized that ammonium pyrrolidinedithioocarbamate (PDTC) - a well-known inhibitor of NF-B could inhibit the development of atherosclerosis in this experimental model. We used apoE/LDLR - DKO mouse model, which is considered as a one of the best models to study the anti-atherosclerotic effect of drugs. In this model PDTC inhibited atherogenesis, measured both by "en face" method (25,15±2,9% vs. 15,63±0,6%) and "cross-section" method (565867±39764 µm2 vs. 291695±30384 µm2). Moreover, PDTC did not change the profile of cholesterol and triglycerides in blood. To our knowledge, this is the first report that shows the effect of PDTC on atherogenesis in gene-targeted apoE/LDLR - double knockout mice.
8

Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies

67%
Czech A., Piatkiewicz P., Taton J.
Archivum Immunologiae et Therapiae Experimentalis
|
2009
|
tom 57
|
nr 6
467-473
9

P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases

67%
Takenouchi T., Sekiyama K., Sekigawa A., Fujita M., Waragai M., Sugama S., Iwamaru Y., Kitani H., Hashimoto M.
Archivum Immunologiae et Therapiae Experimentalis
|
2010
|
tom 58
|
nr 2
91-96
10

Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies

67%
Agnihotri S., Burrell K. E., Wolf A., Jalali S., Hawkins C., Rutka J. T., Zadeh G.
Archivum Immunologiae et Therapiae Experimentalis
|
2013
|
tom 61
|
nr 1
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.